ArticleFrontiers in microbiology2026
Green-synthesized ZnO-MnO nanocomposite as a potent antimicrobial and antibiofilm agent: protein leakage mechanism and synergistic interaction with cefotaxime.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Multidrug-resistant (MDR) Methods: In this study, zinc oxide-manganese oxide bimetallic nanocomposite (ZnO-MnO BNC) was successfully synthesized using potato peel extract through a green synthesis approach. The synthesized nanocomposite was characterized using UV-Vis spectroscopy, FTIR, TEM, and XRD analyses. Its biological activities, including cytotoxic, antibacterial, antibiofilm, bactericidal, and synergistic effects with cefotaxime, were evaluated. Results: UV-Vis spectroscopy showed characteristic absorption peaks at 300 and 380 nm, confirming nanocomposite formation. FTIR analysis identified the functional groups responsible for bioreduction and stabilization, along with Zn-O and Mn-O bonds. TEM analysis revealed nanosized particles ranging from 10 to 60 nm with an average size of approximately 35 nm, while XRD confirmed the crystalline structure of ZnO and MnO phases. Biological evaluation demonstrated moderate toxicity toward WI-38 normal cells (IC50 = 168.34 μg/mL) and strong anticancer activity against Hep-G2 and MCF-7 cell lines, with IC50 values of 30.56 and 56.1 μg/mL, respectively. The ZnO-MnO BNC exhibited potent antibacterial activity against MDR Discussion: The findings highlight the potential of biogenic ZnO-MnO BNC as an eco-friendly nanoplatform with promising antimicrobial and anticancer applications. The strong antibacterial, antibiofilm, and synergistic activities suggest its possible use as an alternative strategy to combat MDR bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.